San Diego, California--(Newsfile Corp. - January 30, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novo Nordisk A/S (NYSE: NVO) securities between November 2 ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

The results put Novo back into the hotly contested race for which drugmaker can deliver the most weight loss from a next-generation product. The shares rose as much as 14% in Copenhagen ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial. Shares were 7 ...

The amount Medicare spent on Ozempic, Wegovy, and Rybelsus between November 2023 and October 2024 represents roughly 36% of Wall Street's consensus estimate for Novo Nordisk's total revenue in 2024.

LVMH (LVMHF) has reclaimed its spot as the biggest company in Europe, overtaking Novo Nordisk (NYSE ... that the luxury goods market is bouncing back from its post-Covid slump.

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new trial, adding to growing threats to the Danish company’s early ...

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... 2025's first US bank IPO 2:04 PM UTC · Updated ago category Wall St set for subdued open after jobs data 2:03 PM UTC · Updated ...

(Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the ...

Novo Nordisk presents a compelling 'Strong Buy ... Therefore, NVO has vast financial flexibility behind its back, which can be used to fuel both organic and inorganic growth.

Jan 16 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, hopes to double the size of its recently acquired contract drugmaker Catalent over five ...

Back in December 2024, Novo completed the acquisition of Catalent in an all-cash transaction valued at approximately $16.5 billion. The purpose of this acquisition was to sell Catalent's three ...